Candel Therapeutics Inc (CADL)
Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
News
Promising Update on the Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
FDA Accelerates Approval for Candel Therapeutics* Pioneering Pancreatic Cancer Treatment, CAN-2409
Candel Therapeutics Streamlines Operations to Fast-track Groundbreaking Cancer Treatments
CADL Dominates Fiscal Q3 of 2023, Setting the Stage for Unprecedented Growth
CADL Outshines Predictions with Noteworthy Achievement in Fiscal Year Ending June 30, 2023
A deficit of $-0.30 per Share at the over the July to September 30 2022 time-frame